Seagen, Inc. (SGEN)
| Market Cap | 31.64B |
| Revenue (ttm) | 2.38B |
| Net Income (ttm) | 597.27M |
| Shares Out | 181.63M |
| EPS (ttm) | 3.21 |
| PE Ratio | 53.49 |
| Forward PE | 217.39 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 380,059 |
| Open | 174.47 |
| Previous Close | 173.90 |
| Day's Range | 170.79 - 175.00 |
| 52-Week Range | 133.20 - 202.60 |
| Beta | 0.82 |
| Analysts | Buy |
| Price Target | 189.00 (+10.2%) |
| Est. Earnings Date | Oct 28, 2021 |
About SGEN
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company markets ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment of metastatic urothelial cancers; and TUKYSA, an oral small molecule tyrosine kinase inhibitor for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer. I...
Financial Performance
Financial StatementsAnalyst Forecast
According to 20 analysts, the average rating for Seagen stock is "Buy." The 12-month stock price forecast is 189.00, which is an increase of 10.25% from the latest price.
News
Earnings Preview: Seattle Genetics (SGEN) Q3 Earnings Expected to Decline
Seattle Genetics (SGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Seagen's (SGEN) Cancer Portfolio Strong, Stiff Rivalry a Worry
Seagen (SGEN) focuses on improving sales of its marketed drugs that are approved for different types of cancer indications. Stiff competition in the target market remains a woe.
3 Biotech Stocks You Can Buy and Hold for the Next Decade
Balance risk and reward with these proven drugmakers.
Astellas and Seagen Complete Enrollment in EV-103 Trial Cohort K Combining PADCEV® (enfortumab vedotin-ejfv) with Pem...
TOKYO and BOTHELL, Wash., Oct. 12, 2021 /PRNewswire/ -- Astellas Pharma Inc. (TSE:4503, President and CEO: Kenji Yasukawa, Ph.D.
Seagen to Host Conference Call and Webcast Discussion of Third Quarter 2021 Financial Results on October 28, 2021
BOTHELL, Wash.--(BUSINESS WIRE)--Seagen Inc. (Nasdaq: SGEN) today announced that it will report its third quarter 2021 financial results on Thursday, October 28, 2021 after the close of U.S. financial m...
Attention Biotech Investors: Mark Your Calendar For October PDUFA Dates
Following a mixed month for regulatory approvals, biotech investors now turn toward a month of plenty as far as Food and Drug Administration decisions are concerned. Four new molecular entities, or NMEs...
Seagen (SGEN) Completes Enrollment in Colorectal Cancer Study
Seagen (SGEN) enrolls the last patient in the phase II MOUNTAINEER study evaluating Tukysa in combination with Herceptin, and as a single agent for treating HER2-positive metastatic colorectal cancer.
Seagen Announces Last Patient Enrolled in Phase 2 MOUNTAINEER Trial Evaluating TUKYSA® (Tucatinib) Regimen in HER2-Po...
BOTHELL, Wash.--(BUSINESS WIRE)--Seagen Announces Last Patient Enrolled in Phase 2 MOUNTAINEER Trial Evaluating TUKYSA® Regimen in HER2-Positive Metastatic Colorectal Cancer
Japan's MHLW Approves PADCEV® (enfortumab vedotin) for Advanced Urothelial Cancer
TOKYO and BOTHELL, Wash., Sept. 27, 2021 /PRNewswire/ -- Astellas Pharma Inc. (TSE:4503, President and CEO: Kenji Yasukawa, Ph.D.
Seagen (SGEN) Gets Early FDA Nod for Tivdak in Cervical Cancer (Revised)
The FDA grants accelerated nod to Seagen (SGEN) and Genmab's Tivdak for treating adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy.
Seagen (SGEN) Gets Early FDA Nod for Tivdak in Cervical Cancer
The FDA grants accelerated nod to Seagen (SGEN) and Genmab's Tivdak for treating adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy.
FDA Gives Accelerated Approval to Seagen - Genmab's ADC In Cervical Cancer
The FDA handed an accelerated approval to Seagen Inc (NASDAQ: SGEN) and Genmab A/S' (NASDAQ: GMAB) Tivdak (tisotumab vedotin-tftv, or TV). The nod comes for second-line patients with recurrent or metast...
Seagen to Host Conference Call and Webcast Discussion on September 21, 2021 to Discuss TIVDAK™ (tisotumab vedotin-tft...
BOTHELL, Wash.--(BUSINESS WIRE)--Seagen Inc. (Nasdaq: SGEN) will host a conference call and webcast on Tuesday, September 21, 2021 to discuss the U.S. Food and Drug Administration approval of TIVDAK™ (t...
Seagen, Genmab Present Tisotumab Vedotin Combo Data In Cervical Cancer
Seagen Inc (NASDAQ: SGEN) and Genmab A/S (NASDAQ: GMAB) have interim data from two Phase 1b/2 innovaTV 205 trial cohorts. The trial is evaluating its antibody-drug conjugate tisotumab vedotin (TV) in re...
Genmab and Seagen Present Interim Results From the innovaTV 205 Study for Tisotumab Vedotin Combination Therapy Treat...
Media Release
3 Top Healthcare Stocks to Buy for September
Catalysts are on the horizon for these bargain stocks.
Seagen to Present at the Morgan Stanley 19th Annual Global Healthcare Conference
BOTHELL, Wash.--(BUSINESS WIRE)--Seagen Inc. (Nasdaq: SGEN) today announced that management will participate in a virtual fireside chat at the Morgan Stanley 19th Annual Global Healthcare Conference on ...
Seagen to Highlight Research From 16 Presentations Across Multiple Tumor Types at ESMO 2021
BOTHELL, Wash.--(BUSINESS WIRE)--Seagen Inc. (Nasdaq: SGEN) today announced data and trials in progress from its diverse and growing portfolio of marketed and investigational therapies will be presented...
Seagen Bets On China's ADC In $2.6B Cancer Deal
Seagen Inc (NASDAQ: SGEN) and RemeGen Co Ltd have entered into an exclusive worldwide licensing agreement to develop and commercialize disitamab vedotin. For $200 million upfront, Seagen is getting ex-A...
Seagen and RemeGen Announce Exclusive Worldwide License and Co-Development Agreement for Disitamab Vedotin
BOTHELL, Wash. & YANTAI, China--(BUSINESS WIRE)--Seagen Inc. (Nasdaq: SGEN), a world leader and pioneer in antibody-drug conjugate (ADC) therapies, and RemeGen Co., Ltd. (9995.HK), a leading innovative ...
Seagen (SGEN) Q2 Earnings Beat Estimates, Revenues Surge Y/Y
Seagen (SGEN) reports narrower-than-expected loss for the second quarter of 2021 while revenues beat estimates.
Seattle Genetics (SGEN) Reports Q2 Loss, Tops Revenue Estimates
Seattle Genetics (SGEN) delivered earnings and revenue surprises of 22.95% and 9.24%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Seagen Reports Second Quarter 2021 Financial Results
BOTHELL, Wash.--(BUSINESS WIRE)--Seagen Inc. (Nasdaq:SGEN) today reported financial results for the second quarter and six months ended June 30, 2021. The Company also highlighted ADCETRIS® (brentuximab...